NCT03601078 is the Phase 2 multi-cohort KarMMa-2 trial. Public readouts tied to this exact trial have been explicitly framed as positive: BMS said cohorts 2a/2c showed durable responses and predictable safety, and later cohort 2b reporting described a favorable benefit-risk profile with frequent, deep, durable responses. No cited trial-specific public source frames KarMMa-2 negatively.
ClinicalTrials.gov identifies NCT03601078 as KarMMa-2, a Phase 2, multicohort study of bb2121/ide-cel in relapsed/refractory and high-risk multiple myeloma.
For KarMMa-2, BMS said cohorts 2a/2c showed durable responses and predictable safety; it further said Abecma demonstrated complete and durable responses in a significant proportion of patients.
This trial-specific summary says a single ide-cel infusion in KarMMa-2 cohort 2b had a favorable benefit-risk profile with frequent, deep, durable responses and manageable safety.
The intrinsic forecast suggests a 60% probability of a positive outcome, which is higher than the current market price of 52.3%. Given the portfolio constraints, buying YES shares is feasible and offers a potential... Steady-state cap reduced request to $553.60.
Intrinsic probability (92%) significantly exceeds the market price (51.9%), creating a substantial value gap. The trial is completed, removing execution risk. Buying YES shares maximizes exposure to this mispricing.
Intrinsic probability (65%) is above market price (51.8%), indicating YES shares are undervalued. The gap is meaningful. Portfolio has cash and a buy cap, enabling a full BUY_YES trade to capture the mispricing.
KarMMa-2 has already presented highly positive data across multiple cohorts at major conferences (e.g., ORR >87% and CR >71% in cohorts 2b/2c). The market is drastically underpricing the known positive trial outcome.
Intrinsic 68% > market 51% (17% edge). Buy max allowed $1000 YES shares (~1945 shares at $0.513) for positive EV. No position, ample cash, no sell constraints bind.
